Items Tagged ‘Multikine’

August 21, 2017

U.S. FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head & Neck Cancer Trial


CEL-SCI Corporation today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the Company’s Phase 3 cancer study with Multikine* (Leukocyte Interleukin, Inj.) has been removed and that all clinical trial activities under this Investigational New Drug application may resume. […]

View full entry

Tags: Head and Neck Cancer, immunotherapy, interleukin, Leukocyte, Multikine, News